Partial federal government shutdown
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
Transcranial magnetic stimulation for treatment of selected conditions
Transcranial magnetic stimulation (TMS) is a noninvasive technique used to stimulate areas of the brain associated with mood regulation and delivers intense magnetic pulses into the brain. There is a growing evidence base that TMS may be efficacious, with fewer or more tolerable side effects, and has led to growing interest in applying TMS to a broad set of conditions, most often those deemed treatment resistant.
Status: Decision completed
Why is TMS being reviewed?
This health technology assessment (HTA) reviews the efficacy, safety, and cost-effectiveness of TMS to assist the State of Washington's Health Technology Clinical Committee (HTCC) in determining coverage of TMS for the following selected behavioral health disorders: depression; anxiety disorders including generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD); posttraumatic stress disorder (PTSD); and addiction disorders including tobacco use disorder and substance use disorder (SUD).
Primary criteria ranking
- Safety = Low/Medium
- Efficacy = Medium/High
- Cost = Medium/High
Documentation
| Type | Materials |
|---|---|
| Assessment (2023) | |
| Related topics |
Assessment timeline
- Draft key questions published: July 8, 2022
- Public comment period: July 8 to July 22, 2022
- Final key questions published: August 23, 2022
- Draft report published: January 5, 2023
- Public comment period: January 5 to February 6, 2023
- Final report published: February 21, 2023
- HTCC public meeting: March 17, 2023
- Draft findings and decision published: March 31, 2023
- Public comment period: March 31 to April 14, 2023
- Final findings and decision published: June 29, 2023